Last reviewed · How we verify

SHR2554 analog tablets; Chidamide — Competitive Intelligence Brief

SHR2554 analog tablets; Chidamide (SHR2554 analog tablets; Chidamide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histone deacetylase inhibitor. Area: Oncology.

phase 3 Histone deacetylase inhibitor Histone deacetylases Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SHR2554 analog tablets; Chidamide (SHR2554 analog tablets; Chidamide) — Jiangsu HengRui Medicine Co., Ltd.. Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SHR2554 analog tablets; Chidamide TARGET SHR2554 analog tablets; Chidamide Jiangsu HengRui Medicine Co., Ltd. phase 3 Histone deacetylase inhibitor Histone deacetylases
Chidamide+ Fulvestrant Chidamide+ Fulvestrant Liaoning Cancer Hospital & Institute marketed HDAC inhibitor + selective estrogen receptor degrader (combination therapy) Histone deacetylases (HDAC) + Estrogen receptor alpha (ERα)
Low dose valproate Low dose valproate Mario Negri Institute for Pharmacological Research marketed Histone deacetylase (HDAC) inhibitor Histone deacetylases (HDACs)
Vorinostat (VOR) Vorinostat (VOR) University of North Carolina, Chapel Hill marketed Histone deacetylase (HDAC) inhibitor Histone deacetylases (HDAC1, HDAC2, HDAC3, HDAC6, HDAC8)
Romidepsin + CHOP Romidepsin + CHOP The Lymphoma Academic Research Organisation phase 3 HDAC inhibitor + chemotherapy combination Histone deacetylases (HDAC)
Purinostat Mesylate for Injection Purinostat Mesylate for Injection Chengdu Zenitar Biomedical Technology Co., Ltd phase 3 Histone deacetylase inhibitor Histone deacetylases
Tucidinostat, Azacitidine combined with CHOP Tucidinostat, Azacitidine combined with CHOP Peking Union Medical College Hospital phase 3 Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen Histone deacetylases, DNA methyltransferases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histone deacetylase inhibitor class)

  1. Celgene · 1 drug in this class
  2. Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class
  3. Evopoint Biosciences Inc. · 1 drug in this class
  4. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
  5. Medical University of Vienna · 1 drug in this class
  6. Merck Sharp & Dohme LLC · 1 drug in this class
  7. NCIC Clinical Trials Group · 1 drug in this class
  8. PharmaMar · 1 drug in this class
  9. Telik · 1 drug in this class
  10. Tianjin Medical University Cancer Institute and Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SHR2554 analog tablets; Chidamide — Competitive Intelligence Brief. https://druglandscape.com/ci/shr2554-analog-tablets-chidamide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: